How next-generation sequencing is opening the door for drug discovery
The Wellcome Trust Sanger Institute’s Kim Judge explains how Next Generation Sequencing forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery…
Next generation sequencing offers unparalleled genomic resolution, allowing users to discriminate between single bases of the genetic code. It can be generated at ever increasing speed and ever decreasing costs. By no means a saviour – able to answer any and all questions – it nevertheless plays a role in the generation of data to be mined. Today, it forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery.
Different next-generation sequencing technologies have different strengths and weaknesses. Some next-generation sequencing technologies, such as 454 Life Sciences owned by Roche, are no longer commercially available. Others are still in production, such as Life Technologies’ SOLiD platform and Ion Torrent’s semiconductor sequencing, but are not as widely used as Illumina, the current market leader.